BNGO · Bionano Genomics, Inc.

Bionano Genomics announced a sudden leadership change, terminating CEO Erik Holmlin effective May 5, 2026. Chairman Al Luderer, 77, steps in as interim CEO and interim principal financial officer. Luderer brings over 50 years of experience, including prior CEO roles at Indi Molecular and Integrated Diagnostics. His compensation includes a $600,000 base salary, a pro-rated bonus opportunity up to $400,000, and a $4,000 monthly stipend. Christopher Twomey was appointed Lead Independent Director and will serve on the Compensation Committee. The company intends to conduct a search for a permanent CEO. The press release emphasizes a seamless transition and Luderer's deep familiarity with Bionano, having served on the board since 2011. This change signals a strategic pivot and may create near-term uncertainty, but the appointment of an experienced insider aims to maintain stability.